Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Genzyme

This article was originally published in The Gray Sheet

Executive Summary

Genzyme: Proposes a buyout of minority interest in Integrated Genetics Laboratories following a Feb. 10 announcement by a committee of IG directors that "various strategic alternatives" are being considered. Genzyme currently owns about 69% of the firm's outstanding shares. The proposal would give public stockholders of IG .12368 shares of Genzyme General Division Common Stock for each IG share. Genzyme estimates the total transaction to be valued at $14 mil...
UsernamePublicRestriction

Register

MT003476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel